Since ICIs treatment relieves T cell tolerance mediated by PD-1/PD-L1 or CTLA-4, CD8+ T cells that originally remained unresponsive to these “self” antigens are activated, thus triggering cross-attacks on normal melanocytes expressing the same antigens (on-target, off-tumor effect) (110). This evidence concerns the gene CD8A and neoplasm.